FDA Approval: Palbociclib (Ibrance) for Breast Cancer

An accelerated approval, and why the label says so

On February 3, 2015, the Food and Drug Administration approved Ibrance. That is the brand name for palbociclib. The application was NDA 207103, held by Pfizer. It was reviewed as a new molecular entity, under priority review.

The approved use: palbociclib in combination with letrozole, for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer, as initial endocrine-based therapy for metastatic disease.

The label then adds a sentence that most coverage left out. "This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial."

Accelerated approval means FDA cleared the drug on a measure expected to predict benefit. The real proof was still to come. That is a deliberate trade: earlier access, in exchange for more uncertainty.

What CDK4/6 does

Cells divide in stages, with checkpoints between them. Two enzymes push a cell past one of those checkpoints. They are called cyclin-dependent kinase 4 and 6, or CDK4 and CDK6. The checkpoint they open is the one between growth and copying DNA.

In hormone receptor-positive breast cancer, estrogen signaling helps drive that machinery. Palbociclib blocks CDK4 and CDK6, so cells stall at the checkpoint instead of dividing.

Letrozole works on the other side of the same problem. It is an aromatase inhibitor. It lowers the amount of estrogen the body makes after menopause. Together the two drugs hit the growth signal and the engine it drives. Our page on hormone therapy for breast cancer explains the hormone half of that pair.

What "ER-positive, HER2-negative" means

After a biopsy, the laboratory tests the tumor for three things: the estrogen receptor, the progesterone receptor and a protein called HER2. Those results sort breast cancer into groups that need different drugs.

ER-positive means the cancer's growth responds to estrogen. Hormone-blocking drugs are then on the table. HER2-negative means HER2-directed drugs are not. This approval sits exactly in that overlap. Someone outside it is outside the indication. Our page on biomarker testing covers how those results are produced.

The trial, and its size

Study 1, the trial known as PALOMA-1, randomized 165 women: 84 to palbociclib plus letrozole and 81 to letrozole alone. Median age was 63. Nearly all, 98 percent, had metastatic disease, and 48 percent had disease in internal organs.

The main measure was progression-free survival assessed by the treating investigators, using standard response criteria.

Median progression-free survival was 20.2 months with palbociclib plus letrozole. The 95 percent confidence interval ran from 13.8 to 27.5. With letrozole alone it was 10.2 months, interval 5.7 to 12.6. The hazard ratio was 0.488, interval 0.319 to 0.748. Among women with measurable disease, tumors shrank by a set amount in 55.4 percent on the combination and 39.4 percent on letrozole alone.

Two qualifiers belong beside those numbers. A later independent review of the scans gave a hazard ratio of 0.621, with an interval of 0.378 to 1.019. That range crosses 1. And when the final analysis was done, overall survival data were not mature. Only 37 percent of events had occurred.

Living with the side effects

The dominant one is neutropenia, a drop in neutrophils, the white blood cells that fight bacterial infection. In Study 1, neutropenia of any grade occurred in 75 percent of women on the combination against 5 percent on letrozole alone. Grade 3 was 48 percent and grade 4 was 6 percent.

Those are large numbers, and they shape the routine. Blood counts are checked before starting and during treatment, and doses are reduced or delayed when counts fall. FDA noted that the median time to the first episode of any-grade neutropenia was 15 days, and the median duration of grade 3 or worse neutropenia was 7 days.

No cases of febrile neutropenia, meaning a fever alongside very low neutrophils, occurred in Study 1, though such events have been reported elsewhere in the palbociclib program. Infections overall were more common on the combination, 55 percent against 34 percent.

Other reactions in at least 10 percent included low white cells, fatigue, anemia, colds, nausea, mouth soreness, hair loss, diarrhea, low platelets, poor appetite, vomiting, weakness, nerve symptoms in the hands and feet, and nosebleeds. Eight percent on the combination stopped the drug for good because of a side effect, against 3 percent on letrozole alone.

Where this sits

For 2026 the American Cancer Society projects 321,910 new female breast cancers in the United States and 42,140 deaths; SEER republishes that forecast beside its own measurements. About 6 percent are already at a distant stage when found. Five-year relative survival across all stages was 91.9 percent for women diagnosed from 2016 through 2022.

That last figure covers every stage together. It is a group statistic about women diagnosed years ago, and it says nothing about the metastatic setting this approval addressed, or about any individual.

What this does not mean

• It does not show that palbociclib helped women live longer. Survival data were immature at approval. That is why the approval was accelerated rather than full.
• Progression-free survival measures the time before scans show growth. It is not the same as feeling better or living longer, and the two can diverge.
• It applies to a defined group: postmenopausal, ER-positive, HER2-negative, advanced disease, first endocrine-based treatment.
• A 165-person trial is small. That is part of why the independent review's confidence interval was so wide.
• Labels change, and this describes February 2015. Later trials and revisions have moved the picture since.

Our guides to clinical trial phases and breast cancer give the wider background.

Sources

• https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf
• https://www.cancer.gov/types/breast
• https://seer.cancer.gov/statfacts/html/breast.html

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.